Further, addition of FGF-2 to breast cancer cell lines in vitro impairs the effects of non-steroidal AIs and tamoxifen whilst downregulation of FGFR1 by siRNAs sensitises breast cancer cells to these agents5. The gene discussed is FGFR1; the disease is breast carcinoma.